Follow up ALIFE study

Follow up ALIFE study - Follow up ALIFE

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON39500

Enrollment

364

Registered

2012-03-27

Start date

2013-04-22

Completion date

Unknown

Last updated

2024-05-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

recurrent miscarriage

Interventions

None listed

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: participation in the previously performed ALIFE study (Kaandorp, NEJM, 2010)

Exclusion criteria

Exclusion criteria: none

Design outcomes

Primary

Measure	Time frame
Primairy study parameters are: - Annexin A5 M2 haplotype and live birth in these women in different treatment arms in the ALIFE trial - Anti β2 glycoprotein antibodies and live birth in these women in different treatment arms in the ALIFE trial - HCGβ and LHβ gene variants and live birth in these women	—

Secondary

Measure	Time frame
Secundary study parameters are: - Annexin A5 M1 haplotype Biobank containing DNA, RNA, citrated blood, heparin blood, EDTA blood, serum and plasma of women with recurrent miscarriage	—

Countries

Netherlands

Outcome results